article thumbnail

Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT Antibody, ISB 2001

Express Pharma

Professor of Haematology, University of Melbourne and Director of Haematology, St Vincents Hospital Melbourne. The post Ichnos Glenmark Innovation presents first clinical data from phase 1 study of Trispecific TREAT Antibody, ISB 2001 appeared first on Express Pharma.

article thumbnail

Join Us for an HPM Webinar: Recent Hospital Controlled Substance Diversion Cases — Cautionary Tales; Tuesday, October 3, 2023: 12:00-12:45

FDA Law Blog: Biosimilars

More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Heart failure: clinical trials update 2022

European Pharmaceutical Review

NTLA-2001, a novel CRISPR/Cas9-based therapy in the first-ever human gene editing trial ( NCT04601051 ) in vivo (in the body), reduced transthyretin (TTR) proteins by at least 90 percent in amyloidogenic transthyretin (ATTR) cardiomyopathy patients, 28 days after a single IV infusion, with benefits lasting four to six months.

Labelling 118
article thumbnail

Nuclear Pharmacist by Day, DJ by Night

Pharmacy Is Right For Me

I worked in Dallas from 95-2001, then moved to NYC, then years later went to the University of Colorado for the NTPD program and received the PharmD. This saved the Nuclear Pharmacies money and time usually spent on training Hospital and Retail pharmacists who left those settings for Nuclear. What led you to this career path?

Hospitals 130
article thumbnail

Reminder: HP&M Webinar on Recent Hospital Controlled Substance Diversion Cases — Cautionary Tales; Tuesday, October 3, 2023: 12:00-12:45

FDA Law Blog: Biosimilars

More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.

article thumbnail

Episode 890: How to Succeed at Journal Club Without Really Trying

Pharmacy Joe

For example, if the new article is about glucose control in the ICU, you can be sure that the letter to the editor will mention other landmark trials such as 2001 article by Van Den Berghe and NICE-SUGAR.

article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

A gradual approach and education Recognising the potential challenges and burdens that a complete shift to ePI might pose, there is support for a gradual implementation, especially in hospital settings and for products administered by healthcare professionals. References European Commission, (26 April 2023). Article 63 EMA (29 January 2020).